CAGE Bio开始对CGB-500进行第2b阶段试验,这是对外皮皮肤炎的一种新的专题治疗。 CAGE Bio initiates Phase 2b trial for CGB-500, a new topical treatment for atopic dermatitis.

CAGE Bio公司针对其专题JAK抑制器(CGB-500)启动了第2b阶段试验,旨在治疗影响一个小身体区域的中度至重度同位素性皮炎。 CAGE Bio has launched a Phase 2b trial for its topical JAK inhibitor, CGB-500, aimed at treating moderate to severe atopic dermatitis affecting a small body area. 该药膏是用该公司的离子液体技术开发的,显示出高功效和低系统暴露。 The ointment, developed with the company's ionic liquid technology, shows high efficacy and low systemic exposure. 以往的试验表明,它的业绩超过现有治疗,副作用较少。 Previous trials indicated it outperformed existing treatments with fewer side effects. 由180人参加的新审判将进一步测试其安全性和最佳剂量。 The new trial with 180 participants will further test its safety and optimal dosing.